MedTrace Logo

CHIP in Health and Disease

NCT07780552 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-08-21

No results posted yet for this study

Summary

Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic mutations. Although CH is associated with an increased risk of hematologic malignancies, its greater public health impact derives from its strong association with cardiovascular diseases, including coronary artery disease and stroke. Emerging evidence suggests that CH-associated mutations promote chronic inflammatory signaling in myeloid immune cells, thereby contributing to atherosclerosis and adverse cardiovascular remodeling.

This observational translational study aims to characterize the biological spectrum of clonal hematopoiesis across different stages of disease risk and manifestation. Using state-of-the-art single-cell and multi-omics approaches, the study will compare inflammatory pathways, immune cell states, and mutation-associated molecular programs among healthy individuals without CH, individuals with high-risk CH, and patients with CH-associated hematologic or cardiovascular disease. The ultimate goal is to identify shared and disease-specific mechanisms linking clonal hematopoiesis to adverse clinical outcomes and to generate insights for future preventive, anti-clonal, and anti-inflammatory therapeutic strategies.

Conditions

  • Clonal Hematopoiesis
  • Clonal Hematopoiesis of Indeterminate Potential
  • Clonal Cytopenia of Undetermined Significance (CCUS)
  • Myelodysplastic Syndrome
  • Cardiovascular Disease
  • Myocardial Infarction (MI)
  • ST-elevation Myocardial Infarction (STEMI)

Sponsors & Collaborators

  • Medical University Innsbruck

    collaborator OTHER

  • VASCage GmbH

    lead OTHER

Principal Investigators

  • Dominik Wolf · Medical University Innsbruck

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07780552 on ClinicalTrials.gov